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Abstract
Background: In order to unravel the interactions between the epithelium and the extra cellular matrix (ECM) in breast 
tissue progressing to cancer, it is necessary to understand the relevant interactions in healthy tissue under normal 
physiologic settings. Proteoglycans in the ECM play an important role in the signaling between the different tissue 
compartments. The proteoglycan decorin is abundant in the breast stroma. Decreased expression in breast cancer 
tissue is a sign of a poor tumor prognosis. The heparane sulphate proteoglycans syndecan-1 and syndecan-4 promote 
the integration of cellular adhesion and proliferation. The aim of this study was to investigate the gene expression and 
location of decorin, syndecan-1 and syndecan-4 in the healthy breast during the menstrual cycle.
Methods: Tissue from healthy women undergoing breast reduction plastic surgery was examined using 
immunohistochemistry (n = 38) and Real-Time RT-PCR (n = 20). Both parous and nulliparous women were eligible and 
the mean age of the women was 34(+/- 10 years) with regular menstrual cycles (28 +/- 7 days). None of the women 
had used hormonal treatment the last three months. The women were randomized to needle biopsy two months 
before the operation in the follicular or luteal menstrual phase and for another biopsy at the operation in the opposite 
phase. Serum samples were obtained to characterize the menstrual phase. The Wilcoxon signed rank test and Mann 
Whitney test were used for statistical analyses.
Results: By real time-RT-PCR the gene signal for all three proteoglycans; decorin (p = 0.02) and syndecan-1 (p = 0.03) 
and syndecan-4 (p = 0.02) was significantly lower among parous women in the luteal phase than in the follicular phase. 
Immunohistochemistry confirmed the identification of the proteins but no significant difference between menstrual 
phases was observed. Serum samples verified the menstrual phase.
Conclusions: Our study shows, for the first time in the healthy breast, a significantly lower expression of the genes for 
the three proteoglycans, decorin, syndecan-1 and syndecan-4 in the luteal phase during the menstrual cycle. These 
changes were registered under normal physiologic conditions. Since ECM molecules appear to be involved in tumor 
progression, these findings in the normal breast could constitute a base for further studies in women receiving 
hormonal therapy or those with breast cancer.
Background
During the menstrual cycle, the human mammary gland
undergoes histologic changes in both the epithelial and
stromal compartments. In vitro studies have implied that
the extracellular matrix (ECM) plays a role in modulating
proliferation, differentiation and gene expression [1].
Increased synthesis and degradation of the ECM, compo-
nents seems to be associated with breast cancer and its
prognosis [2,3]. Proteoglycans, which are strategically
located on the surface of the ECM cells and in the pericel-
lular matrix, have an important role in stromal-epithelial
interactions and signaling and are able to control the
activity of extracellular regulatory proteins [4]. In young
premenopausal women, 15% of breast tissue consists of
epithelium: this is gradually replaced by fat tissue later in
life. Among postmenopausal women, only 5% of the
breast contains epithelium [5] while breast stroma com-
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posed of collagen, fibroblasts, endothelial cells, adipo-
cytes and a macromolecular network of proteoglycans
accounts for more than 80% of the breast volume [6].
Several authors have described the pattern of the pro-
teoglycan expression in the light of breast cancer progres-
sion [7,8]. The expression of decorin, which is abundant
in the stroma, can for example, indicate the prognosis of a
tumor [9] and decorin can also diminish tumor growth in
rat experiments [10]. The syndecans are heparan sulphate
proteoglycans (HSPG) that are expressed in the basement
membrane and the epithelial cells. Among postmeno-
pausal women with breast cancer or dense-mammo-
graphic breast tissue, the expression of these
proteoglycans changes from the epithelium to the stroma
[11,12].
Only a few workers have addressed the role of the pro-
teoglycans in the stroma under normal physiologic condi-
tions in the healthy breast [13]. Various hormonally
regulated epithelial and stromal events, possibly associ-
ated with changes in the extracellular matrix, occur dur-
ing the menstrual cycle. Knowledge of the normal
expression of gene signals for these proteoglycans during
the menstrual cycle is therefore of importance. The pur-
pose of this study was to examine the location and gene
expression of the proteoglycans decorin, syndecan-1 and
syndecan-4 in healthy breast tissue, with particular atten-
tion to the ECM, during the follicular and luteal phases of
the menstrual cycle.
Methods
Subjects
Women on the waiting list for mammoplasty surgery for
breast reduction at the Department of Plastic Surgery,
University Hospital, Uppsala, Sweden were recruited for
this study. Healthy non-pregnant premenopausal women
were eligible if they had regular menstrual periods (28 ± 7
days) and had not used hormonal contraception during
the last three months. Nulliparous (n = 15) or parous (n =
23) women were included. The study was approved by the
Ethics Committee of the Faculty of Medicine, Uppsala
University, Uppsala, Sweden.
Study design
T h e  p a r t i c i p a n t s  w e r e  r a n d o m i z e d  t o  b r e a s t  r e d u c t i o n
surgery timed according to their menstrual cycle phase
(follicular or luteal). A preoperative mammography and a
needle biopsy, preferably in the right breast, were per-
formed during the alternate menstrual phase, two
months before the operation and at the operation in the
opposite phase. Serum samples were collected on the
same day to confirm the assumed phase. On the opera-
tion day, breast tissue and a second serum sample were
collected. The reduction mammoplasty surgery was per-
formed according to routine procedures.
Sampling of breast tissue
For all women the samples were taken two months before
and at the operation. Samples were formalin-fixed, as well
a s  f r o z e n  i n  l i q u i d  n i t r o g e n  a t  b o t h  o c c a s i o n s .  T w o
months before the operation a needle biopsy was taken.
The biopsy was taken from the right breast using an auto-
matic double spring gun "Manan" pro-Mag 2.2 with a 22
mm stroke lens and a 14 Gauge needle (2.1 mm: ×16 cm
with a 17 mm notch U. S. Biopsy division of Promix Inc
USA). Immediately after the main surgery, parenchymal
tissue was dissected from the adipose tissue, frozen in liq-
uid nitrogen and stored at -70° until analyzed. At the
same time parenchymal tissue was fixed in 4% paraform-
aldehyde and later paraffin-embedded. The paraffin-
embedded tissue was sectioned and mounted on Fisher
slides. The slides were stored in a dark room at a cool
temperature.
The immunohistochemistry analysis was carried out on
biopsies from 15 nulliparous and 23 parous women.
RNA-preparations containing sufficient material for real-
time reverse-transcription polymerase chain reaction
(RT-PCR) analyses were available from 20 women.
Immunohistochemistry
Formalin-fixed tissue taken two months before the opera-
tion and at the reduction mammoplasty was paraffin-
embedded. The paraffin-embedded tissue was sectioned
and mounted on Fisher slides. The slides with paraffin-
embedded sections were preheated for 30 minutes at 60°
in an oven. The slides were then heated with DIVA
DECLOAKER (Biocare Medical, Concord, CA) in a 2100-
RETRIEVER (Histolab, Gothenburg, Sweden) for 20 min-
utes for antigen retrieval, after which the tissue sections
were rinsed in HOT RINSE (Biocare Medical) to guaran-
tee complete deparaffinization. After rinsing in Tris-buff-
ered saline (TBS) (Biocare Medical), endogenous
peroxidaze activity in all sections was quenched by incu-
bation in PEROXIDAZED (Biocare Medical) for 5 min-
utes in darkness at room temperature. After incubation
with BACKGROUND SNIPER (Biocare Medical) for 10
minutes, the sections were incubated with the primary
monoclonal antibodies decorin (conc. 1 mg/ml, Code No
270425, Clone 6-B-6, 1:3000; Seikagaku, Tokyo, Japan)
and syndecan-1, (Code No MCA681, Clone No B-B4
1:400; Serotec, Oxford, England) and syndecan-4 (conc.
200 μgIgG/ml, Code No Sc-9499, 1:800; Santa Cruz, CA,
USA) for 60 minutes (Table 1). Subsequently, the biotin-
free detection system mouse-probe HRP polymer kit
M A C H  3 ™  ( B i o c a r e  M e d i c a l ,  W a l n u t  C r e e k ,  C A )  w a s
used for decorin and syndecan-1, while the Goat-HRP
polymer kit MACH 3™ was used for syndecan-4. The
reaction was developed using the diaminobenzidine DAB
kit (Biocare Medical, Walnut Creek, CA). The TBS rinse
was used between each step. The sections were thenHallberg et al. Reproductive Biology and Endocrinology 2010, 8:35
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counterstained with hematoxylin. Finally, the slides were
mounted with Pertex® (Histolab products AB, Gothen-
burg, Sweden). In each assay, controls for specificity were
carried out using primary antibodies preincubated with
blocking peptides for syndecan-4 (Santa Cruz, Biotech-
nology) and with mouse IgG1 negative control for synde-
can-1 and decorin. In all cases, immunoreactivity in the
breast biopsy was classified blind by two independent
observers using conventional light microscopy (GH, EA).
The staining intensity was graded on a scale of (0) = no
staining, (1) = faint staining, (2) = moderate staining and
(3) = strong staining.
Sample procedure for Real-Time RT-PCR
Tissue homogenization and extraction of RNA
The biopsies were homogenized frozen using a dismem-
branation apparatus (Retsch KG, Haan, Germany) to
achieve a fine powder from which the total RNA was
extracted using a Trizol reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer's instructions.
Reverse Transcription (RT)
The concentration of total RNA was determined by Nan-
odrop™ 1000, only samples exhibiting an OD260/OD280
ratio higher than 1,8 were used and the quality of the total
RNA was verified by running an agarose gel. The RT
reaction used on 1 μg total RNA 1 μl (200 ng) of pd (N)6.
Random Hexamer 5'-Phosphate primers (Amersham Bio-
sciences, Pistacaway, NJ, USA), 1 μl of 10 mM dNTP
(Amersham Biosciences) and sterile water added to 12 μl.
The mixture was incubated for 5 min at 65°C, cooled and
centrifuged. The reaction mixture consisting of 4 μl of 5 ×
First-Strand Buffer, 2 μl of 0.1 M DTT (Invitrogen, Carls-
bad, California) and 1 μl (40 U/μl) Protector Rnase Inhib-
itor (Roche, Mannheim, Germany), was added and the
resulting mixture was incubated for 2 min at 25°C. 1 μl
(200 U/μl) of Superscript™ Rnase H-  Reverse Tran-
scriptase (Invitrogen, Carlsbad, California, USA) was
added to each tube and mixed and incubated in 10 min-
utes at 25°C. The RT step was carried out at 42°C for 50
min, followed by heating at 70°C for 15 min to inactivate
the enzyme. The cDNA was stored at -70°C until used.
Real-Time PCR
The levels of mRNA encoding decorin, syndecan-1, and
syndecan-4 were quantified using the Applied Biosystems
7300 Real-Time PCR system (Applied Biosystems, Foster
city, CA, USA). All determinations were performed in
triplicate in the Taqman Universal PCR master Mix
(Applied Biosystems, Foster city, CA, USA) on 96-well
optical PCR plates. Appropriate primers and probes were
obtained from commercially available Taqman®  gene
expression assays (Applied Biosystems). Assay IDs and
Reference Sequence database accession numbers are pre-
sented in Table 1. Ribosomal 18 S RNA (Assay ID
4319413E, Applied Biosystems), hormone-stable and
expressing ribosomal RNA, was used as a house-keeping
gene. Each reaction used 5 μl diluted cDNA correspond-
ing to 10 ng total RNA in 12.5 μl Universal Master Mix,
1.25 μl assay mixture and 6.25 μl sterile water. The real-
time PCR reaction was carried out according to the man-
ufacturer's protocol. The threshold cycles (CT), at which
an increase in reporter fluorescence above the baseline
signal was first detected, were determined. 18S was used
as endogenous control and for normalization (ΔCT)of the
mRNA levels for the gene of interest. The endogenous
control was subtracted from respective gene giving the
ΔCT as a reflection of the relative mRNA expression.
Mean value of (ΔCT) for women in the follicular and
Table 1: Assay ID used in real-time RT-PCR and antibodies used in Immunohistochemistry
Real Time PCR Antibodies
Assay ID Reference 
Sequence 
database 
accession 
number
No, 
manufacturer
Type Dilution
Syndecan-1 Hs 00174579_m1 NM_001006946.1 MCA 681, Serotec, 
Oxford, England
Mouse 
monoclonal
1:400
Syndecan-4 Hs 00161617_m1 NM_002999.2 Sc-9499, Santa 
Cruz, CA, USA
Goat polyclonal 1:800
Decorin Hs 00370385_m1 NM_133503.2 270425, 
Seikagaku, Tokyo, 
Japan
Mouse monclonal 1:3000Hallberg et al. Reproductive Biology and Endocrinology 2010, 8:35
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luteal phase were calculated using the Mann Whitney U
test. To compare the women in the follicular and luteal
phase, the calculations of relative gene expression were
done using the ΔΔCT method, where the women in the
follicular menstrual phase were used as a control group.
Because the amount of product doubles in each cycle the
relative gene expression was calculated using the formula
2-ΔΔCT, given in the manufacturer's instructions. Serial
dilutions were performed to measure cDNA with the
housekeeping gene 18S on all biopsies to validate the
exponential amplification previous to the Real-Time
PCR. Serial dilutions of breast tissue cDNA made from
purchased total RNA (Ambion, Austin, TX, USA) were
used for validation of the experiment.
Serum analysis
Commercial kits were used for analyzing the serum levels
of estradiol and progesterone (Amerlite®, Johnson & John-
son clinical diagnostics Ltd, Amersham, UK), and sex
hormonebinding globulin (SHBG: Delfia, Wallac Oy,
Turku, Finland). The analyses were performed according
to the manufacturer's manual.
Statistical analysis
The matched pair Wilcoxon signed rank test was
employed to compare the paired immunohistochemistry
results. Comparisons between the two independent
gr o u ps  i n  t h e  r e a l -t i m e  R T  PCR  t e s t  w e r e  ca rri ed  o u t
using the Mann-Whitney U test.
Results
Women in the study had a mean age of 34(+/- 10) years
and a normal age of menarche 12.6 (+/- 1.5) years. The
women had a BMI of 26.5(+/- 5) kg/m2 and the serum
level of estradiol and progesterone verified the corre-
sponding menstrual phase (Table 2). Gene expression
was calculated by ΔCT, normalized by the endogenous
control 18S and using the mean value for the follicular
and luteal phase. To compare the menstrual phases, the
women in the follicular phase were a control group giving
the magnitude of the fold decrease. Gene expression of
syndecan-4 was significantly lower in the luteal phase
than in the follicular phase of the menstrual cycle in the
total group with a 2.6 fold decrease in expression (p =
0.03) and in parous women a more than five times lower
expression (p = 0.02) in the luteal phase compared to the
follicular (figure 1a and 1b). This was accompanied by an
almost comparative five-fold lower gene expression for
syndecan-1 in the luteal phase in parous women (p =
0.03). Gene expression of the small leucine-rich proteo-
glycan (SLRP) decorin was more than seven times lower
in the luteal phase (p = 0.02) in parous women compared
to the follicular phase(figure 1a and 1b). Although the
same pattern of expression was seen in nulliparous
women (n = 6) the difference did not reach statistical sig-
nificance. This was probably due to low sample size. All
proteins were well visualized by immunhistochemistry
(figure 2). The staining of decorin in the ECM was strong
Figure 1 A) The mean values of the ΔCT for women in the follicular 
and luteal phase in syndecan-1, syndecan-4 and decorin. 18 S was 
used as an endogenous control and was used for normalization of the 
mRNA levels for the gene of interest. The endogenous control was 
subtracted from respective gene giving the ΔCT as a reflection of the 
relative mRNA. Since a higher ΔCT corresponds to a lower mRNA ex-
pression the ΔCT values are presented inverted as 10/ΔCT. B) The 
mRNA expression of the proteoglycans syndecan-1, syndecan-4 
and decorin in human breast tissue from 20 women, including 14 
parous women. The value from the follicular phase was used as con-
trol, using the ΔΔCT method.
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but there was no difference in the staining intensity in the
follicular as well as in the luteal phase. Stained syndecan-
1 and -4 was clearly identified in the epithelial and the
basement membranes. There were no significant differ-
ences in the distribution of syndecan-1 between the men-
strual cycle phases. There was a prominent difference
between patients rather than within each patient (figure
3). The inter-observer variations were for syndecan-1,
syndecan-4 and decorin; rs = 0.82, rs = 0.91 and rs = 0.48;
p < 0.0001 for all. All control sections were negative, as
shown in Figures 2 a), c) and 2 e).
Discussions
To our knowledge, this is the first time that the pattern of
gene expression for three important proteoglycans in the
healthy human breast has been shown during the men-
strual cycle. We found that the gene expression for synde-
can-1, syndecan-4 and decorin was significantly lower in
the luteal phase than in the follicular phase of the men-
strual cycle in parous women. Identification of the pro-
teins was confirmed by immunhistochemistry, although
significant correlations between the two menstrual
phases were not obtained with this methodology.
Earlier studies of the healthy human breast during the
menstrual cycle have reported various histologic changes
in the epithelium and stroma [14,15]. For example, Fergu-
son et al. [13] used the indirect immunofluorescence to
describe a pattern of increased staining of the ECM in
weeks 1 and 4 of the menstrual cycle and reduced stain-
ing in weeks 2 and 3, while collagens remained
unchanged. Stoeckelhuber et al. used an ultrastructural
study to show a different organization between the pro-
teoglycan-collagen associations in the luteal phase; this
was explained by higher water content in the breast at
this time [16]. The increase in distance was more promi-
nent in the intralobular tissue than in the interlobular
stroma. The importance of the interactions and co-
dependencies between the epithelial cells and the ECM in
breast tissue has been highlighted in the regulation of
tumor progression [17]. Most of the gene expression
Figure 2 Immunohistochemical staining of syndecan-1 (a, b), 
syndecan-4 (c, d) and decorin (e, f) in the follicular and luteal 
phases of the menstrual cycle. The magnification was ×400 for syn-
decan-1 and syndecan-4 and × 200 for decorin. Negative controls were 
inserted in the follicular pictures a), c) and e). The matched pair Wilcox-
on signed rank test was used to compare the immunohistochemistry 
results.
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Figure 3 Quantification of pair-matched immunohistochemical 
staining of syndecan-1, syndecan-4 and decorin in the follicular 
and luteal menstrual phase. Semiquantitative scale from 0 to +++ 
was used.
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required for transformation of normal tissue to a cancer
in situ occurs early in the stroma and the epithelium,
where stroma and epithelium cooperates and for acquisi-
tion of the invasive phenotype, the stroma is dominant
over the epithelium[18]. Stromal changes have been doc-
umented in both pre-invasive breast lesions and tumors
[19]. The SLRP decorin is found abundantly in the ECM.
Decorin has been shown to inhibit the growth of both
primary breast cancer xenografts and metastatic spread
by inactivating the oncogenic ErbB2 protein in breast car-
cinoma cells [10] and downregulating members of the
ERb tyrosine kinase family, leading to growth inhibition
[10]. Previous studies have reported downregulation of
decorin in breast cancer tissue [2], a situation which has
been associated with a poor prognosis [9]. In a study on a
rodent mammary carcinoma, Goldoni et al. described
marked reduction in both primary tumor growth and
metastatic spread after decorin protein was injected [20].
The physiologic reduction of gene expression in the
luteal phase of the menstrual cycle may be a consequence
of the effect of ovarian hormones [13]. Other authors
have speculated on the gonoidal hormones effect on the
ECM [21]. Progesterone, elevated during the luteal phase,
interacts with growth factors (for example, HGF, EGF and
IGF-1) and gives rise to both synergistic and inhibitory
effects, influenced by the composition of the ECM [21].
The addition of progestin to estrogen hormonal replace-
ment therapy increases the risk of cancer in the breast,
while the opposite effect is well known in the uterine
endometrium. In oophorectomized rats, the total levels
of glycosaminoglycans decreased but, on the administra-
tion of estradiol, the levels of some HSPGs were
increased. Sunil et al. found that progesterone adminis-
tration, either alone or in combination with estradiol
increased the levels of some proteoglycans in the rat
mammary gland[22]. The syndecans, which are HSPGs
can be either up-regulated or downregulated during the
progression of a malignancy. Both syndecan-1 and synde-
can-4 are overexpressed in an estrogen receptor -nega-
tive, highly proliferative breast carcinoma subtype [8].
Syndecan-1 can be redistributed from the epithelial cells
to the stroma compartment in postmenopausal cancers
[12,23,24]. In fact, increased expression of syndecan-1
has been associated with increased mammographic den-
sity as well as re-distribution from the epithelium to the
stroma among postmenopausal women [11].
In our study of healthy breast tissue among premeno-
pausal women, a decrease in gene signaling for syndecan-
1 and -4 was observed in the luteal phase. Germeyer et al.
examined syndecans-1 and -4 in the endometrium of the
uterus and found a reciprocal expression with upregula-
tion in the luteal phase of the menstrual cycle [25]. This
was confirmed by Lai et al., who found that the expres-
sion of syndecan-1 was increased in the mid-luteal phase
in uterine epithelial cells but was downregulated in the
stroma during the early to late luteal phase, coinciding
endometrial remodeling of the uterus [26]. From our
results we can only conclude that decorin, syndecan-1
and syndecan-4 are regulated during the menstrual cycle
in human breast tissue, providing an indication for fur-
ther studies to clarify the influence of exogenous hor-
mones.
Conclusions
This study reveals the possible regulation of the proteo-
glycans syndecan-1, syndecan-4 and decorin during the
menstrual cycle.
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Table 2: Clinical characteristics of women included in the study
Age
Year
BMI
(kg/m2)
Menarche
(age)
P4 foll. 
(nmol/l)
P4 lut. 
(nmol/l)
E2 foll 
(pmol/l)
E2 lut. 
(pmol/l)
SHBG 
foll. 
(nmol/l)
SHBG 
lut. 
(nmol/l)
n 37 37 37 34 35 35 35 29 29
mean/
SD
34 ± 10 26.5 ± 5 12.6 ± 1.5 2.1 ± 
1.5
15.0 ± 
17.8
394.2 
± 317
355.5 
± 302
49.2 ± 
22.2
49.6 ± 
8.7Hallberg et al. Reproductive Biology and Endocrinology 2010, 8:35
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